In the autoimmune disease type 1 diabetes (T1D), the genetic association with the IL-2 pathway in mice12 and in humans13,14, combined with preclinical studies15,16, have provided a strong rationale for the development of low-dose (LD)-IL-2 immunotherapy. This evidence concerns the gene IL2 and type 1 diabetes mellitus.